Background. The JAK2V617F mutation is present in the majority of patients with polycythaemia vera and in approximately half of patients with essential thrombocythaemia and primary myelofibrosis. In this study we compare the results of JAK2V617F mutation detection using three different molecular techniques in the same group of patients affected by essential thrombocythaemia. Patients and methods. The JAK2 mutation was investigated with a qualitative method in 115 consecutive outpatients with a diagnosis of essential thrombocythaemia made according to WHO 2001 criteria. In 48/115 (41.7%) the allele burden was also evaluated with two different qualitative methods, of which one was a method developed in-house and the other was a commercially available method. Results. The JAK2V617F mutation was detected by the qualitative method in 81/115 (69.6%) of the patients. Among the 48/115 patients in whom all three methods were applied, the qualitative method detected the mutation in 38 (79%). According to the quantitative method developed in-house, the mutation was present in 35/48 (73%) of the patients: of these, 2/35 (5.7%) patients were homozygous for the JAK2V617F mutation. The commercial quantitative method showed the mutation in 37/48 (77%) patients: of these, 9/37 (18%) patients were homozygous. Three of the 13 patients in whom no mutation was detected by the in-house method were positive for the JAK2V617F according to the commercial method. In one patient the search for the JAK2V617F mutation was positive with the in-house method but negative with the commercial kit. Conclusion. Detection of the JAK2V617F mutation may depend on the molecular technique used. Considering that detection of this mutation will not only have a diagnostic value, but also a role in treatment given the development of JAK2 V617F pathway inhibiting drugs, indications on a reference molecular diagnostic technique for JAK2V617F assessment and quantification of its allele burden from a panel of experts are warranted.

Comparison of JAK2V617F mutation assessment employing different molecular diagnostic techniques

AMBROSETTI, Achille;PIZZOLO, Giovanni
2009-01-01

Abstract

Background. The JAK2V617F mutation is present in the majority of patients with polycythaemia vera and in approximately half of patients with essential thrombocythaemia and primary myelofibrosis. In this study we compare the results of JAK2V617F mutation detection using three different molecular techniques in the same group of patients affected by essential thrombocythaemia. Patients and methods. The JAK2 mutation was investigated with a qualitative method in 115 consecutive outpatients with a diagnosis of essential thrombocythaemia made according to WHO 2001 criteria. In 48/115 (41.7%) the allele burden was also evaluated with two different qualitative methods, of which one was a method developed in-house and the other was a commercially available method. Results. The JAK2V617F mutation was detected by the qualitative method in 81/115 (69.6%) of the patients. Among the 48/115 patients in whom all three methods were applied, the qualitative method detected the mutation in 38 (79%). According to the quantitative method developed in-house, the mutation was present in 35/48 (73%) of the patients: of these, 2/35 (5.7%) patients were homozygous for the JAK2V617F mutation. The commercial quantitative method showed the mutation in 37/48 (77%) patients: of these, 9/37 (18%) patients were homozygous. Three of the 13 patients in whom no mutation was detected by the in-house method were positive for the JAK2V617F according to the commercial method. In one patient the search for the JAK2V617F mutation was positive with the in-house method but negative with the commercial kit. Conclusion. Detection of the JAK2V617F mutation may depend on the molecular technique used. Considering that detection of this mutation will not only have a diagnostic value, but also a role in treatment given the development of JAK2 V617F pathway inhibiting drugs, indications on a reference molecular diagnostic technique for JAK2V617F assessment and quantification of its allele burden from a panel of experts are warranted.
JAK 2; myeloproliferative; diseases
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/337853
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact